# Hypertrophic cardiomyopathy

Condition · id `cardio:hypertrophic-cardiomyopathy` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: HCM

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

Hypertrophic cardiomyopathy is a condition in which the heart muscle becomes thicker than normal. In most people the thickening is in the wall between the two lower chambers, and it can block the flow of blood out of the heart. Most people with the form that has no other cause have a normal life expectancy, but some develop an abnormal heart rhythm that may be life-threatening and a small number develop heart failure. The risk of sudden death is higher than usual, although it remains uncommon. In the United States the label of the medicine mavacamten gives symptomatic obstructive disease as its indication.

## Technical summary

MeSH descriptor D002312 (Cardiomyopathy, Hypertrophic). The MeSH scope note describes a form of cardiac muscle disease with left or right ventricular hypertrophy, frequent uneven involvement of the heart septum and normal or reduced left ventricular volume. The MedlinePlus Genetics page describes the nonsyndromic form, which is not explained by another cause and does not affect other parts of the body, so its statements on life expectancy and sudden death may not fit every person with the condition. A 2024 US guideline covers management of the condition; only its abstract was read for this atlas.

## Claims, with the population each applies to

## Context: People with cardiomyopathy, as described in MeSH, MedlinePlus, MedlinePlus Genetics and NHLBI reference pages

Recipient: Recipient not specified; Population: People with cardiomyopathy in general. The pages are written for the public or as a vocabulary and give no study population. They describe adults and also say that newborns and children can have cardiomyopathy. The MedlinePlus Genetics pages describe the nonsyndromic forms, which are not explained by other causes and do not affect other parts of the body.; Care setting: General health information for the public; no care setting is stated; Geography: United States (pages of US government agencies); the MeSH vocabulary is international; Life stage: Not limited by age. NHLBI says people of any age can have cardiomyopathy, including newborns and children, and names peripartum cardiomyopathy as a form that affects some women around pregnancy.; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive statement)

### The MeSH scope note describes hypertrophic cardiomyopathy as a form of heart muscle disease with thickening of the left or right ventricle, frequent uneven involvement of the heart septum and normal or reduced left ventricular volume. MedlinePlus Genetics describes it, in its nonsyndromic form, as thickening of the heart muscle, most often in the wall between the lower chambers, which can obstruct the flow of blood out of the heart. It says most people with this form have a normal life expectancy, that some develop an abnormal heart rhythm that may be life-threatening, that a small number develop heart failure, and that the risk of sudden death is increased although uncommon.

- Category: Description
- Evidence stage: Evidence stage unknown
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: People with cardiomyopathy in general. The pages are written for the public or as a vocabulary and give no study population. They describe adults and also say that newborns and children can have cardiomyopathy. The MedlinePlus Genetics pages describe the nonsyndromic forms, which are not explained by other causes and do not affect other parts of the body.; Care setting: General health information for the public; no care setting is stated; Geography: United States (pages of US government agencies); the MeSH vocabulary is international; Life stage: Not limited by age. NHLBI says people of any age can have cardiomyopathy, including newborns and children, and names peripartum cardiomyopathy as a form that affects some women around pregnancy.; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive statement)
- Limitations: Vocabulary and patient-education pages from US government sources. The MedlinePlus Genetics page describes the nonsyndromic form, which is not explained by another cause and does not affect other parts of the body, so it may not describe every person with the condition. The pages give no study, no size of risk and no population beyond the general public.
- Last checked: 2026-10-30
- Sources:
  1. Supports: MeSH scope note for descriptor D002312 (Cardiomyopathy, Hypertrophic) (Dataset, edition MeSH linked-data record of the preferred concept M0003464 of descriptor D002312, fetched 2026-10-30. The scope note is on this concept record, not on the descriptor record.) <https://id.nlm.nih.gov/mesh/M0003464>
     Locator: scopeNote.@value. Retrieved 2026-10-30T19:43:07Z. Source state: Current. Version fingerprint: e2dfd8316c24d06935f24c456e33a57491edce6e41d54c3730008928e88c950e.
     How it applies: MeSH scope note of the descriptor Cardiomyopathy, Hypertrophic.
  2. Supports: Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated June 16, 2026. The address uses the older name familial hypertrophic cardiomyopathy; the page title is Nonsyndromic hypertrophic cardiomyopathy.) <https://medlineplus.gov/genetics/condition/familial-hypertrophic-cardiomyopathy/>
     Locator: Description, para 1, sentence 1. Retrieved 2026-10-30T19:44:00Z. Source state: Current. Version fingerprint: 55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45.
     How it applies: What the condition is.
  3. Supports: Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated June 16, 2026. The address uses the older name familial hypertrophic cardiomyopathy; the page title is Nonsyndromic hypertrophic cardiomyopathy.) <https://medlineplus.gov/genetics/condition/familial-hypertrophic-cardiomyopathy/>
     Locator: Description, para 2, sentence 2. Retrieved 2026-10-30T19:44:00Z. Source state: Current. Version fingerprint: 55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45.
     How it applies: Where the thickening usually occurs.
  4. Supports: Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated June 16, 2026. The address uses the older name familial hypertrophic cardiomyopathy; the page title is Nonsyndromic hypertrophic cardiomyopathy.) <https://medlineplus.gov/genetics/condition/familial-hypertrophic-cardiomyopathy/>
     Locator: Description, para 2, sentence 3. Retrieved 2026-10-30T19:44:00Z. Source state: Current. Version fingerprint: 55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45.
     How it applies: Obstruction of blood flow.
  5. Supports: Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated June 16, 2026. The address uses the older name familial hypertrophic cardiomyopathy; the page title is Nonsyndromic hypertrophic cardiomyopathy.) <https://medlineplus.gov/genetics/condition/familial-hypertrophic-cardiomyopathy/>
     Locator: Description, para 4, sentence 1. Retrieved 2026-10-30T19:44:00Z. Source state: Current. Version fingerprint: 55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45.
     How it applies: Life expectancy of most people with the nonsyndromic form.
  6. Supports: Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated June 16, 2026. The address uses the older name familial hypertrophic cardiomyopathy; the page title is Nonsyndromic hypertrophic cardiomyopathy.) <https://medlineplus.gov/genetics/condition/familial-hypertrophic-cardiomyopathy/>
     Locator: Description, para 4, sentence 2. Retrieved 2026-10-30T19:44:00Z. Source state: Current. Version fingerprint: 55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45.
     How it applies: Abnormal heart rhythm.
  7. Supports: Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated June 16, 2026. The address uses the older name familial hypertrophic cardiomyopathy; the page title is Nonsyndromic hypertrophic cardiomyopathy.) <https://medlineplus.gov/genetics/condition/familial-hypertrophic-cardiomyopathy/>
     Locator: Description, para 4, sentence 3. Retrieved 2026-10-30T19:44:00Z. Source state: Current. Version fingerprint: 55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45.
     How it applies: Heart failure.
  8. Supports: Nonsyndromic hypertrophic cardiomyopathy (MedlinePlus Genetics) (Webpage, edition Page fetched 2026-10-30. The page says it was last updated June 16, 2026. The address uses the older name familial hypertrophic cardiomyopathy; the page title is Nonsyndromic hypertrophic cardiomyopathy.) <https://medlineplus.gov/genetics/condition/familial-hypertrophic-cardiomyopathy/>
     Locator: Description, para 4, sentence 4. Retrieved 2026-10-30T19:44:00Z. Source state: Current. Version fingerprint: 55387d73362d9a3ae21a7fac384499277ea4183402dcc10dcd9e91c51c89ca45.
     How it applies: Sudden death risk.

## Connected pages

- Hypertrophic cardiomyopathy is a type of cardiomyopathy: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Related condition: sudden cardiac arrest: Sudden cardiac arrest (`cardio:sudden-cardiac-arrest`)
- Files under this front: Medicines (`cardio:front-medicines`)
- Related to: Left ventricular hypertrophy (`cardio:left-ventricular-hypertrophy`)
- Evaluated for this: Aficamten (`cardio:aficamten`) [a claim, not a settled fact; see claim `cardio:claim-fda-myqorzo-label-indications` and its context]
- Evaluated for this: Mavacamten (`cardio:mavacamten`) [a claim, not a settled fact; see claim `cardio:claim-mavacamten-label-indication` and its context]
- Evaluated for this: Septal reduction therapy (myectomy, alcohol septal ablation) (`cardio:septal-reduction-therapy-myectomy-alcohol-septal-ablation`) [a claim, not a settled fact; see claim `cardio:claim-fda-dehydrated-alcohol-label-indication` and its context]
- Evaluated for this: Septal reduction therapy (myectomy, alcohol septal ablation) (`cardio:septal-reduction-therapy-myectomy-alcohol-septal-ablation`) [a claim, not a settled fact; see claim `cardio:claim-pmc-srt-two-forms` and its context]
- Evaluated for this: Septal reduction therapy (myectomy, alcohol septal ablation) (`cardio:septal-reduction-therapy-myectomy-alcohol-septal-ablation`) [a claim, not a settled fact; see claim `cardio:claim-pmc-srt-arrhythmia-meta-analysis` and its context]

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 32 registry trials

## Provenance

Content hash: d549816b879e18c22f00eeb14a946dbcec40f0d560d9b1e45cc748d1b99818be
Last substantive edit: 2026-10-30
Evidence last checked: 2026-10-30
